Connor Clark & Lunn Investment Management Ltd. Decreases Stock Position in Medpace Holdings, Inc. $MEDP

Connor Clark & Lunn Investment Management Ltd. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 128,599 shares of the company’s stock after selling 30,253 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Medpace were worth $66,120,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Fifth Third Wealth Advisors LLC raised its position in Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares in the last quarter. HighPoint Advisor Group LLC increased its stake in shares of Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after buying an additional 22 shares during the period. Portside Wealth Group LLC increased its stake in shares of Medpace by 2.5% during the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after buying an additional 27 shares during the period. Whittier Trust Co. of Nevada Inc. raised its holdings in Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after acquiring an additional 27 shares in the last quarter. Finally, M&T Bank Corp raised its holdings in Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their price target for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Truist Financial reduced their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Barclays upgraded shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price for the company in a research note on Friday, March 6th. Finally, Royal Bank Of Canada started coverage on Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $486.67.

Medpace Stock Up 2.3%

NASDAQ:MEDP opened at $477.72 on Thursday. The company has a market capitalization of $13.56 billion, a PE ratio of 31.22, a P/E/G ratio of 2.24 and a beta of 1.44. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The stock’s 50 day moving average price is $528.39 and its 200 day moving average price is $539.24.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.